Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Almirall announces dosing alteration for Eklira

Almirall announces dosing alteration for Eklira

27th January 2010

Almirall announced this week that it will halt its authorisation application for Eklira in the EU while it considers alternative dosing recommendations.

The outcome of a recent phase III trial into the chronic obstructive pulmonary disease (COPD) treatment displayed the benefits of its twice-daily (BID) administering.

As a result, the company will now give full priority to the development and filing of the BID dosing of Eklira (aclidinium bromide), putting on hold the filing of the once daily regimen.

Jorge Gallardo, president and chief executive officer of Almirall, commented: “This strategic decision has been taken following discussions with European regulatory experts and key opinion leaders from which it became clear that BID dosing is likely to provide a superior benefit for COPD patients.”

Last week, Almirall highlighted the success of a psychiatry convergence which it recently hosted in Barcelona.

The meeting attracted over 300 experts in psychiatry and was the ninth event to be held so far.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.